People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Satori Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $22.3M | $464.6M | 2010 |
| Follica, Inc | — | Pharmaceuticals | Series A | $15.2M | $4.2M | 2010 |
Christopher Ehrlich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Ehrlich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daphne Zohar | 2 | 4 |
| Kevin Bitterman | 1 | 15 |
| Edward Mathers | 1 | 12 |
| David Schnell | 1 | 7 |
| Ilan Zipkin | 1 | 6 |
| Chris Ehrlich | 1 | 6 |
| Steven Holtzman | 1 | 3 |
| Bennett Shapiro | 1 | 2 |
| Jeffrey Ives | 1 | 2 |
| Stephen Muniz | 1 | 1 |
| William Ju | 1 | 1 |
| Kirk Raab | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.